Vaginal estrogen and association with dementia: A nationwide population‐based study. Issue 4 (28th July 2021)

• Record Type: Journal Article
• Authors: Pourhadi, Nelsan; Mørch, Lina S.; Holm, Ellen A.; Torp‐Pedersen, Christian T.; Meaidi, Amani
• Is Part Of: Alzheimer's & dementia. Volume 18:Issue 4(2022)
• Page Start: 625
• Page End: 634
• Publication Date: 2021-07-28
• Subjects: Alzheimer's disease -- dementia -- hormone therapy -- nationwide study -- pharmacoepidemiology -- register study -- risk factor -- vaginal estrogen; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12417
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Use of systemic hormone therapy has been positively associated with development of dementia. Little is known about the dose‐dependent effect of vaginal estradiol on dementia risk. Methods: We assessed associations between cumulative dose of vaginal estradiol tablets and dementia in a case‐control study nested in a nationwide Danish cohort of women aged 50 to 60 years at study initiation, who did not use systemic hormone therapy. Each case was age‐matched to 10 female controls. Results: A total of 4574 dementia cases were matched to 45, 740 controls. Cumulative use of vaginal estradiol tablets was not associated with all‐cause dementia; adjusted hazard ratio 1.02 (95% confidence interval [CI] 0.89–1.18) for low dose (< 750 mcg), 1.07 (0.94–1.21) for medium dose (750–2000 mcg), and 0.93 (0.84–1.03) for high dose (> 2000 mcg). Similarly, Alzheimer's disease (AD) only was not associated with vaginal estradiol. Discussion: Exposure to vaginal estradiol tablets was not associated with all‐cause dementia or AD only.